• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Brands are ALWAYS better than generics.

Quote








If generic drugs are so bad, why do Americans spend over 80% of their Rx dollars on Gx's? If generics were so terrible, payors would pay for effective brand drugs because a failed Gx drug costs them more, in the long run, than a working Rx drug. Gx's work largely. There are quality issues within Gx manufacturing, but there are also in the Rx world (to a lesser extent). The overall is that Gx's are more cost effective than Rx's when they are available.
 




Anonymous said:
What's great is after these morons learn that 20% can mean the difference between life and death! it will be too late... And The Supreme Court has ruled that they have no redress.

This website is like arguing with children.
Click to expand...

Children like the FDA, and the entire academic medical research field.

Has anyone else noticed that the mental midget who calls everyone else "children" has failed to produce one credible source for bios claims regarding generics. Oh, he has produced a non-peer reviewed opinion piece from a hack who is publicly identified as being bribed by pharma.

This poster is a prime example of why pharma's require people like him to stick to the facts that are included in their detail sheets. If not, they would "go off script", talk about what they think that they know and would then leave the company liable.

He is nothing but a life support unit for a recording that the company give a Ford Taurus to to drive around his Podunk territory to drop off samples and buy lunch for the undedicated docs who will proscribe his branded scam drugs until the govt will not pay for them anymore.

Then, he'll be out teaching high school health to his rural school kids for $33.5 / yr!

hahahahaha
 




"Oh, he has produced a non-peer reviewed opinion piece from a hack who is publicly identified as being bribed by pharma."

You mean like the guy who promoted the benefits of generic drugs to the government right before he took a job with TEVA. Suck on that FACT.
 




Anonymous said:
"Oh, he has produced a non-peer reviewed opinion piece from a hack who is publicly identified as being bribed by pharma."

You mean like the guy who promoted the benefits of generic drugs to the government right before he took a job with TEVA. Suck on that FACT.
Click to expand...

The ENTIRE medical research community agrees with him. There is NO research on the your side.

You are a stupid, crap selling little person who has to cling to stupid FACTS that your FDA Admin to generics co just to sleep at night.

What ever you try and argue here though, you are a slimy pharma rep.
 




Yes... EVERYONE agrees with you. Just like NOBODY questions man-made global warming. You libs always delude yourselves and live within these alrernate-reality bubbles. If you ever stepped outside your Potemkin-Village, you might learn a little about reality.
 




Anonymous said:
Yes... EVERYONE agrees with you. Just like NOBODY questions man-made global warming. You libs always delude yourselves and live within these alrernate-reality bubbles. If you ever stepped outside your Potemkin-Village, you might learn a little about reality.
Click to expand...

Yep, I used the facts the dove the "Brands are ALWAYS better than generics" so change the subject. Fucking moron.
 












Anonymous said:
Except for the heath care insurance subsidized by the fed govt and paid (80%) for by novartis, your employer!

hahahahahaha
Click to expand...

Wtf are you talking about? Think clearly and form complete thoughts before you start typing a series of meaningless hahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahaha
 




Anonymous said:
Wtf are you talking about? Think clearly and form complete thoughts before you start typing a series of meaningless hahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahahaha
Click to expand...

I did and this is:

Except for the heath care insurance subsidized by the fed govt and paid (80%) for by novartis, your employer!

hahahahahaha

I like sticking these facts up ur a$$ and watching you squeeeeel, in response.
 




Anonymous said:
I did and this is:

Except for the heath care insurance subsidized by the fed govt and paid (80%) for by novartis, your employer!

hahahahahaha

I like sticking these facts up ur a$$ and watching you squeeeeel, in response.
Click to expand...

Ok??? Just keep your "facts" and whatever other fantasies you have away from my a$$... That's just creepy.
 




If generics are exactly the same as branded, then explain this FACT:

Problems With Generic Wellbutrin XL

Posted on October 15, 2012 by Roy Stefanik
Earlier this month the Food and Drug Administration (FDA) reported that the Teva Pharmaceuticals generic brand of Wellbutrin XL 300 mg failed to demonstrate therapeutic equivalence and is being removed from the market.* This is the result of a process that began in 2007, shortly after the generic version of Wellbutrin XL 300 mg was approved.** Teva’s generic brand of Wellbutrin XL is called Budeprion XL (bupropion hydrochloride extended-release tablets), and is one of five generic versions of Wellbutrin XL 300 mg approved by the FDA.

Following the approval, the FDA began to receive multiple reports that patients switched from Wellbutrin XL 300 mg to its generic counterparts were experiencing reduced effectiveness, and the FDA found the complaints to be linked specifically to the Teva product.* The FDA asked Teva to conduct a study to compare its 300 mg product bioequivalence to Wellbutrin XL 300 mg.* Teva began the study, but terminated it in late 2011 because it was unable to recruit enough patients to obtain the necessary data.

In 2010, the FDA decided to sponsor its own bioequivalence study comparing the two products.* It was conducted in 24 adults and was designed to measure both the rate and the extent of release of bupropion in the blood.* The results of this study became available in August 2012, and showed that Budeprion XL 300 mg tablets fail to release bupropion in the blood at either the same rate or same extent as Wellbutrin XL 300 mg.* The generic version releases the drug at a much faster rate and at a concentration of only 75% of Wellbutrin XL.

Bioequivalence studies have not yet been performed on the other four generics, made by Anchen, Actavis, Watson, and Mylan Pharmaceuticals.* The FDA has requested these companies complete their studies and submit their data no later than March 2013.* In the meantime, it is strongly recommended you discuss with your health care provider whether you should use one of the other generic formulations or take the brand name Wellbutrin XL.* You may also want to talk with either your pharmacy or your health insurance company about the difference in price between the brand name (made by GlaxoSmithKline) and other generic versions of the drug.* In the meantime, there is no concern at this time about bioequivalence with the Teva 150 mg version of Budeprion.
 




American Thyroid Association.... The ATA is the leading organization devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health. Hmmm... Do these guys count?

Thyroid Experts Warn of Clinically Important Differences in Potency of FDA-Approved Levothyroxine Products

(FALLS CHURCH, VA)—Two organizations representing more than 5,400 clinical endocrinologists today warned patients taking thyroid medication, prescribing physicians, and pharmacists dispensing these drugs that clinically important differences do, in fact, exist between one recently approved generic levothyroxine preparation and the most widely prescribed brand of levothyroxine. The members of these organizations, the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE), specialize in treatment of hormonal disorders.

Levothyroxine is taken by more than 13 million Americans to treat an underactive thyroid, thyroid gland enlargement, nodules, or cancer. In June, the Food and Drug Administration (FDA) ruled that several generic levothyroxine preparations had the same clinical effect and safety profile as certain branded products. As a result, pharmacists may substitute a patient’s current levothyroxine preparation for another, sometimes without their physician’s approval.

According to bioequivalence data used to acquire FDA approval, one recently approved generic levothyroxine preparation (Sandoz Levothyroxine Sodium) is significantly more potent than the most widely used brand of levothyroxine (Synthroid®). Information from bioequivalence studies submitted to the FDA show that the new generic may be as much as one-eighth more potent (+12.5%) than the widely prescribed branded product.

Furthermore, levothyroxine is a drug known to have a narrow toxic-to-therapeutic ratio with significant clinical consequences of even minor excessive or inadequate dosing. Potential adverse events include symptoms, osteoporosis, atrial fibrillation, worsening of heart disease, preterm delivery in pregnancy, impaired fetal brain development, and high cholesterol.

“Unfortunately, this information confirms our concern that current FDA standards defining the equivalence of levothyroxine products are too lax,” said Carlos Hamilton, MD, AACE President. “Switching between two products could compromise the effectiveness of treatment and even result in serious side effects.”

The ATA and AACE have repeatedly expressed their concerns about the FDA’s recent decision to approve generic substitutes for levothyroxine products and its implications for the millions of Americans who depend on this drug. The societies have also made public their disappointment that the FDA made their decision before considering the input offered by clinical endocrinologists, the recognized experts who care for thyroid patients.
 




Now that I have introduced you to a reality outside of your liberal-bubble that you created for yourself, do you think you might want to rethink this ridiculous statement: "The ENTIRE medical research community agrees with him. There is NO research on the your side."

BTW, this is not about "my side". This is about observing reality, facts and applying basic logic. To dispute the FACT that generics are not equal to branded meds in every way, is to dispute reality and to deny facts.
 




Now I know why you love generics so much. If it weren't for the generic condom with the hole in it, you would never have been born. Plus that generic abortion your Mom tried failed as well. You are truly the product and beneficiary of generics... I forgive you for your misguided position.
 












Top Bottom
Back
Quote